ArticleFrontiers in medicine2026
Association between hematopoietic recovery indicators and minimal residual disease after induction therapy in newly diagnosed pediatric acute myeloid leukemia.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the relationship between peripheral blood and bone marrow hematopoietic recovery indicators and minimal residual disease (MRD) status following induction chemotherapy in pediatric patients with newly diagnosed acute myeloid leukemia (AML), and to evaluate the early predictive value of these indicators for MRD positivity. Methods: Clinical data from 62 pediatric patients with newly diagnosed AML who received standard induction chemotherapy between January 2015 to December 2024 were retrospectively reviewed. Patients were stratified into MRD-negative (MRD < 0.1%, Results: The two groups were well-balanced in baseline characteristics, with no significant differences. Those in the MRD-positive group had significantly lower ANC and PLT nadirs, and prolonged time to ANC and PLT recovery. On day 28, a higher proportion of patients in the MRD-positive group exhibited hypocellular bone marrow, along with impaired granulocytic and megakaryocytic recovery. Spearman analysis showed that PLT recovery time was strongly positively correlated with MRD levels, while PLT nadir showed a strong negative correlation; both correlations were stronger than those observed for ANC-related indicators. Multivariate logistic regression confirmed that delayed PLT recovery and reduced PLT nadir were independent correlates of MRD positivity. The combination of PLT recovery time and PLT nadir achieved an area under the ROC curve (AUC) of 0.820 (95% CI: 0.724 - 0.916) for predicting MRD positivity, with a sensitivity of 84.37% and specificity of 78.21%, significantly outperforming individual indicators. Bootstrap validation confirmed model stability (AUC = 0.798, 95% CI: 0.712 - 0.884). Conclusion: Hematopoietic recovery indicators are closely associated with MRD status in pediatric AML following induction therapy. MRD-positive patients exhibit delayed and poor-quality hematopoietic recovery. Delayed PLT recovery and reduced PLT nadir are robust independent correlates of MRD positivity, and their combined use offers a simple, accessible tool for early MRD risk stratification and efficacy assessment, particularly in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.